Research and Development
Industry Partnership Fuels Research, Advocacy
PhRMA membership expands CSL Behring’s opportunity for cooperation between industry leaders.
A New Home for R&D in Germany
A world-class facility for 500 researchers is set to open in Marburg in the second half of 2022.
A Soldier in the COVID-19 Survivor Corps
“I was a day or two from death,” says Scott Cohen, who lost his father to the virus. He now advocates for others.
Nominations for 2021 Young Investigator Draft
Uplifting Athletes event offers $20,000 grants for rare disease researchers.
Flu Lessons From Australia
Southern Hemisphere offers clues for managing influenza amid COVID-19 pandemic.
Designing Clinical Trials With Patients
CSL Behring’s Deirdre BeVard will join a panel discussion on the topic December 3, but she plans to do a lot of listening.
After a Heart Attack, a 90-Day High-Risk Period
About a quarter of patients are hospitalized again within three months, according to new, real-world data shared at the Ameri…
Collaborating on a COVID-19 Treatment
Hear from leading plasma medicine companies about a new clinical trial for a “hyperimmune.”
Soap Can Kill the Virus That Causes COVID-19
CSL Behring scientists in Germany discovered that sodium laureth sulfate – found in many liquid soaps – works on various surf…
The Fight Against the Pandemic
CSL Behring experts detail progress toward potential COVID-19 therapy to global audiences.
Rare Disease in China
CSL Behring sponsors rare disease summit in China, where the rare disease community is trying to improve quality of life for …